In preclinical studies, PARP inhibitors (such as olaparib) exhibit potent tumoricidal activities on breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, Ewing’s sarcoma, small cell lung carcinoma, and neuroblastoma, among others. This evidence concerns the gene PARP1 and pancreatic neoplasm.